Nanobacteria Implicated in Most All Degenerative Diseases

[Guest guest]

Sinatra is leading preacher of coenzyme q10 as a cure for lots of

things--particularly heart disease; a little off subject of this post,

but you may want to look into that connection, also..

 

 

 

regards, UncBob

 

 

I used to think oxidized LDL cholesterol created the plaque that caused

atherosclerosis (hardening of the arteries).

 

 

http://www.adventist4truth.com/refitted/index.php?HealthPages=nanobacter\

ia

 

Nanobacteria Implicated in Most All Degenerative Diseases

Major Breakthrough in Arterial Health is an excerpt from the June '02

issue of The Sinatra Health Report, the monthly newsletter of Stephen

Sinatra MD FACC, which is reproduced with the permission of Dr. Sinatra

and Phillips Health LLC. If you are interested in N. sanguineum,

Nanobiotic therapy, and EECP, then you will probably be interested in

what Dr. Sinatra has to say about cardiovascular disease and the

treatments available to you - I read Dr. Sinatra's newsletter and so do

my patients. To learn more about Dr. Sinatra and/or to to The

Sinatra Health Report go to http://www.drsinatra.com/ or call Phillips

Health LLC at (800) 211-7643.

 

 

Nanobacteria: Major Breakthrough in Arterial Health

By Stephen Sinatra, MD, FACC, FACN

Like every cardiologist on the planet, I used to think oxidized LDL

cholesterol created the plaque that caused atherosclerosis (hardening of

the arteries). Trouble was, there were many cases of cardiovascular

disease that this theory couldn't account for. Oxidized LDL may be

part of the story, but it's not the full explanation. The exciting

news is that nanobacteria may well be.

 

 

Nanobacteria, formally known as Nanobacterium sanguineum, are so minute

that they eluded researchers for decades. They're 1/1,000 the size

of normal bacteria, and until recently, nobody believed that something

so small could even be alive. It turns out that nanobacteria are not

only very much alive but thriving, and they are damaging our health in

more ways than we could have ever dreamed.

As you know, a mission of mine has been to try to explain how and why

heart disease occurs in people who don't exhibit the traditional

risk factors. If we can hit upon the cause, then we can help prevent

thousands of unexplained deaths each year. There have been numerous

hypotheses, but so many never pan out. Take Chlamydia pneumoniae, the

pathogen that causes acute respiratory disease, for example. Remember

the news reports from just a few years ago that proclaimed infection

with this bacterium probably accounted for much of the unexplained

plaque in people? The hope was that we could treat the C. pneumoniae and

thereby eradicate the plaque. Well, further research uncovered C.

pneumoniae in only a small percentage of all plaque—certainly not

enough to be a pervasive cause. I never jumped on the chlamydia

bandwagon because the research was not convincing and was too often

contradictory.

 

 

When I first heard about nanobacteria, I was skeptical, too. But I have

looked into the subject at length and talked with physicians involved,

and now I'm convinced that the study of nanobacteria will bring

about a whole new understanding of a number of diseases. This kind of

understanding is what leads to treatments and eventually cures.

The Nanobac Story in Brief

 

 

In 1988 Olavi Kajander, M.D., Ph.D., and Neva Ciftcioglu, Ph.D., were

conducting research on mammalian cells at the University of Kuopio in

Finland, work that is ongoing today. As so often happens in basic

medical research, the cells in their cell cultures kept dying. But,

instead of just throwing them out, as researchers usually do, the two

scientists forgot about the dead cell cultures in the incubator. Months

later, they retrieved these cultures and started to investigate an

unusual, hardened film that had formed on the culture surfaces. What

they discovered were tiny bacteria—20–200 nanometers in

size—in calcified shells.

 

 

The discovery of nanobacteria should have been a major moment in

bacterial research history, yet no journal would publish their findings!

The bacteria were so small that no one could believe they were alive. It

was not until 1997 that their findings were finally published in a

medical journal. (This is a good example of how slowly the medical

establishment moves.)

 

 

In their research, Kajander and Ciftcioglu—who have been nominated

for a Nobel prize—found that nanobacteria were social little

creatures, banding together to secrete an irritating toxic film that

causes swelling and inflammation. The film provides them with protection

so they can connect and colonize like slime molds, expanding,

contracting, and moving. Eventually, this film hardens into a shell,

protecting the nanobacteria colony from our body's attempts to clear

it out.

 

 

Even in this calcified state, nanobacteria aren't necessarily

dormant; they can continue to aggregate and reproduce. And our body

doesn't recognize them as a foreign pathogen at this stage.

They're just seen as calcium, so the nanobacteria are free to expand

unchecked. (To see one in the middle of cellular division, and other

photos, visit www.nanobaclabs.com)

Nanobacteria are a bit sluggish at the multiplication game. Unlike most

bacteria, which replicate in minutes or hours, nanobacteria take about

three days to reproduce, which helps explain why their significance may

have been underestimated for so long. This slow replication means that

nanobacteria may be in the body as long as 40 years before symptoms like

inflammation and noticeable plaque develop.

 

 

The biofilm phase of nanobacterial life is one of the most damaging to

human bodies, because the biofilm is a potent toxin that causes the body

to react powerfully with irritation and swelling. Though the

" bugs " themselves cause damage, even more damage is caused by

the body's reaction to them. In other words, the body, in trying to

react to the damage, hurts itself. The body's defenses in turn

trigger several medical markers of inflammation, including the

well-known C-reactive protein (CRP), which helps explain why elevated

CRP levels are a major harbinger of coronary artery disease.

 

 

An Apt Analogy

To help illuminate what the discovery of nanobacteria could ultimately

mean for our health, let's take a look at H. pylori and ulcers. It

was only after years of having patients undergo gastric surgery that

doctors learned a bacterium known as Helicobacter pylori was the culprit

in many ulcers. So surgeons were putting patients with ulcers through

major surgery, cutting their vagus nerve (the extensive cranial nerve

that extends to the abdomen) and revamping part of their small

intestine, when treatment turned out to be easily achieved with

antibiotics in most cases.

 

 

In the same way, interventional cardiologists are going in and cutting

the blood vessels around patients' hearts to bypass plaque-filled

arteries in what has become an alarmingly common procedure. We may learn

that all that's needed for severely calcified arteries is a course

of the right antibiotic. (Actually, nanobacteria treatment is more

complicated, but I'll get to that in a moment.)

 

 

Scientists from the Hungarian Academy of Sciences have reported finding

nanobacteria in more than 60 percent of human artery-clogging plaques

studied. The Hungarians also confirmed and validated previous research

reports of how truly miniscule these bacteria are and therefore how

easily they can enter the body via blood exchange and blood products.

With their protective apatite coat, nanobacteria are highly resistant to

heat, radiation, and all antibiotics—except tetracycline.

 

 

Eradicating N. sanguineum

NanobacLabs, based in Tampa, FL, has been conducting research with a

special therapy that has been instrumental in nanobacterium killing and

along with that, plaque reversal. Nanobac-

Labs researchers have performed a pilot study of 91 patients using the

following protocol on a daily basis over several months:

• 500 mg oral tetracycline

• 1,500 mg EDTA rectal suppository (EDTA is a weak synthetic amino

acid that works as a chelating agent to gradually infiltrate mineral

deposits and pull them away from the cardiovascular system.)

• a mixture of compounds taken by mouth that retards the excretion

of EDTA

 

 

The premise is as follows: Tetracycline is the only antibiotic known to

kill nanobacteria, but it needs a way to infiltrate their calcified

shells. Enter EDTA chelation, which is used to " fluff up " the

plaque, allowing tetracycline access to the bacteria. The added oral

powder keeps the EDTA in your bloodstream longer so the tetracycline has

more time to eradicate the bacteria.

Of the 91 participating patients, the mean decrease in their coronary

artery calcification scores was 58.5 percent after treatment with

NanobacTX therapy for three months. Interestingly, in 19 of those 91

patients 100 percent of coronary artery calcification was eradicated.

These are truly amazing statistics! I know of no other treatment that is

so successful. NanobacLabs is now conducting a much larger study of

plaque reversal, and some of my patients are participating.

A minimum of four months of NanobacTX treatment is necessary to treat

many folks with coronary artery calcification. For those whose plaque

burden is excessive, nine to twelve months (or more) of therapy may be

needed. From the cardiologists reporting back so far, most patients

start seeing a marked improvement in quality of life in four to six

weeks. It is also interesting to note that many patients have reported

the resolution of co-existing illnesses. (See " Diseases Associated

with Calcified Plaque, " page 5.)

 

 

Not a Cure-All

Despite all the promising early news about NanobacTX, it should not be

considered a panacea. First, it needs to be tested in larger clinical

trials of longer duration before I'm confident of its usefulness.

Second, " fluffing " the calcified plaque to allow the

tetracycline ample penetration could possibly precipitate angina. Such

was the case for one of my patients, who had to withdraw from the study.

For now, I would refer those patients with very high calcium scores or

those with angina who have a poor quality of life and are running out of

options. This is where the real beauty of nanobacteria treatment

lies—providing one more card for us physicians to play when the

stakes are the highest. Otherwise, there's so little we can do when

someone's vessels are clogged beyond repair.

Perhaps we'll eventually discover new combinations of procedures.

James Roberts, MD, FACC, of Toledo, Ohio, reports using NanobacTX as a

stepping-stone to EECP. (Enhanced External Counter Pulsation is a

therapy to help the body naturally bypass blocked arteries. See SHR

February 2001 or Dr. Roberts's Web site, www.heartfixer.com, for

more information.)

 

 

What You Can Do Now

The bottom line is that coronary artery disease (as well as many other

diseases) is a process of inflammation. This inflammation can be caused

by nanobacteria and then compounded by traditional risk factors, or it

may be the result of any combination of excess oxidized LDL, lipid

peroxides from saturated fats, cigarette smoking, heavy metal

toxicities, a sedentary lifestyle, and so on. It's still difficult

to say in individual cases what the root cause might be. The science is

just not there yet.

There are a few blood tests to screen for nanobacteria, but none are

conclusive. (If you're in a high-risk group and want more

information about screening now, ask your physician or contact

NanobacLabs directly: 10330 North Dale Mabry Highway, Suite 226, Tampa,

FL 33618; phone 813-264-2241. Ask about their NanobacTest.)

Finally, to gain a better understanding of inflammatory heart disease, I

highly recommend an article in the May 2002 issue of Scientific

American, " Atherosclerosis–the New View " by Dr. Peter Libby.

Although there's no discussion of nanobacterium, and the article is

somewhat technical, it's appropriate for the general reader,

especially my savvy rs. I could spend an entire newsletter on

this topic, but not every reader would be thrilled.

So please read Dr. Libby's article if you're intrigued.

I hope you're as excited as I am about this breakthrough research.

Even as I write this, additional scientific commentary is coming in.

This could be the biggest medical science story of the 21st century.

Rest assured that I'll continue to track the nanobacteria story and

share it with you as it evolves.

References

Ciftcioglu N, et al. Nanobacteria: an infectious cause of kidney stone

formation. Kidney International. 1999;56:1893-1898.

Kajander O, et al. Nanobacteria from blood, the smallest culturable

autonomously replicating agent on Earth. Proc SPIE. 1997;3111:420-28.

Kajander O, et al. Nanobacteria: an alternative mechanism for pathogenic

intra- and extra-cellular calcification and stone formation. Proc Natl

Acad Sci 1998;95:8274-8279.

Libby P. Atherosclerosis: the new view. Scientific American. May 2002:

24-55.

Used with permission of Phillips Health, LLC. To to The

Sinatra Health Report by Dr. Stephen Sinatra, or for more information

about the topics Dr. Sinatra covers in his newsletter, please call (800)

211-7643.

 

 

 

Nanobacteria has been implicated in:

Atherosclerotic Plaque

Blood Disorders

Breast Calcification

[certain] Cancers

Cataracts

Coronary Artery Plaque

Dental Plague

Eczema

Fibromyalgia

Heart Disease

Kidney Stones

Lichen Planus

Liver Cysts

Myelodegenerative disorders such as Multiple Sclerosis, Lou Gehrig's

Disease & Alzheimer's Disease

Osteoarthritis

Polycystic Kidney Disease

Psoriasis

Periodental Disease

Prostate Calcification

Rheumatoid Arthritis

Sclerdoma

Nanobacteria and its pathological calcification are implicated to be

either the cause or instrumental in most ALL degenerative disease

processes.